These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
259 related articles for article (PubMed ID: 9836374)
41. The role of T-cell interleukin-17 in conducting destructive arthritis: lessons from animal models. Lubberts E; Koenders MI; van den Berg WB Arthritis Res Ther; 2005; 7(1):29-37. PubMed ID: 15642151 [TBL] [Abstract][Full Text] [Related]
42. Complementary action of granulocyte macrophage colony-stimulating factor and interleukin-17A induces interleukin-23, receptor activator of nuclear factor-κB ligand, and matrix metalloproteinases and drives bone and cartilage pathology in experimental arthritis: rationale for combination therapy in rheumatoid arthritis. van Nieuwenhuijze AE; van de Loo FA; Walgreen B; Bennink M; Helsen M; van den Bersselaar L; Wicks IP; van den Berg WB; Koenders MI Arthritis Res Ther; 2015 Jun; 17(1):163. PubMed ID: 26081345 [TBL] [Abstract][Full Text] [Related]
43. Stimulation of BMP-2 expression by pro-inflammatory cytokines IL-1 and TNF-alpha in normal and osteoarthritic chondrocytes. Fukui N; Zhu Y; Maloney WJ; Clohisy J; Sandell LJ J Bone Joint Surg Am; 2003; 85-A Suppl 3():59-66. PubMed ID: 12925611 [TBL] [Abstract][Full Text] [Related]
44. Pathogenesis of bone and cartilage destruction in rheumatoid arthritis. Goldring SR Rheumatology (Oxford); 2003 May; 42 Suppl 2():ii11-6. PubMed ID: 12817090 [TBL] [Abstract][Full Text] [Related]
45. [Inflammatory cytokine mediated anti-anabolic effects: a potential mechanism in rheumatoid cartilage degeneration]. Aigner T; Vornehm SI; Belke J; von der Mark K; Kirchner T Verh Dtsch Ges Pathol; 1996; 80():282-7. PubMed ID: 9065028 [TBL] [Abstract][Full Text] [Related]
46. Pro- and anti-inflammatory cytokines in rheumatoid arthritis. Isomäki P; Punnonen J Ann Med; 1997 Dec; 29(6):499-507. PubMed ID: 9562516 [TBL] [Abstract][Full Text] [Related]
47. Detection of cytokines at the cartilage/pannus junction in patients with rheumatoid arthritis: implications for the role of cytokines in cartilage destruction and repair. Chu CQ; Field M; Allard S; Abney E; Feldmann M; Maini RN Br J Rheumatol; 1992 Oct; 31(10):653-61. PubMed ID: 1393370 [TBL] [Abstract][Full Text] [Related]
48. Lessons for joint destruction from animal models. van den Berg WB Curr Opin Rheumatol; 1997 May; 9(3):221-8. PubMed ID: 9204257 [TBL] [Abstract][Full Text] [Related]
49. [Regulation of cartilage matrix synthesis by chondrocytes]. Hardingham TE; Rayan V; Lewthwaite JC Rev Rhum Ed Fr; 1994 Nov; 61(9 Pt 2):93S-98S. PubMed ID: 7858613 [TBL] [Abstract][Full Text] [Related]
50. A model of inflammatory arthritis highlights a role for oncostatin M in pro-inflammatory cytokine-induced bone destruction via RANK/RANKL. Hui W; Cawston TE; Richards CD; Rowan AD Arthritis Res Ther; 2005; 7(1):R57-64. PubMed ID: 15642143 [TBL] [Abstract][Full Text] [Related]
51. Cytokine modulation of plasminogen activator inhibitor-1 (PAI-1) production by human articular cartilage and chondrocytes. Down-regulation by tumor necrosis factor alpha and up-regulation by transforming growth factor-B basic fibroblast growth factor. Campbell IK; Wojta J; Novak U; Hamilton JA Biochim Biophys Acta; 1994 Jul; 1226(3):277-85. PubMed ID: 8054359 [TBL] [Abstract][Full Text] [Related]
52. Hypothesis: cartilage catabolic cofactors in human arthritis. Hollander AP; Dieppe PA; Atkins RM; Elson CJ J Rheumatol; 1993 Feb; 20(2):223-4. PubMed ID: 8474056 [TBL] [Abstract][Full Text] [Related]
53. Chimeric anti-IL-17 full-length monoclonal antibody is a novel potential candidate for the treatment of rheumatoid arthritis. Bai F; Tian H; Niu Z; Liu M; Ren G; Yu Y; Sun T; Li S; Li D Int J Mol Med; 2014 Mar; 33(3):711-21. PubMed ID: 24378614 [TBL] [Abstract][Full Text] [Related]
54. T cell dependence of chronic destructive murine arthritis induced by repeated local activation of Toll-like receptor-driven pathways: crucial role of both interleukin-1beta and interleukin-17. Joosten LA; Abdollahi-Roodsaz S; Heuvelmans-Jacobs M; Helsen MM; van den Bersselaar LA; Oppers-Walgreen B; Koenders MI; van den Berg WB Arthritis Rheum; 2008 Jan; 58(1):98-108. PubMed ID: 18163514 [TBL] [Abstract][Full Text] [Related]
55. Cartilage damage and bone erosion are more prominent determinants of functional impairment in longstanding experimental arthritis than synovial inflammation. Hayer S; Bauer G; Willburger M; Sinn K; Alasti F; Plasenzotti R; Shvets T; Niederreiter B; Aschauer C; Steiner G; Podesser BK; Smolen JS; Redlich K Dis Model Mech; 2016 Nov; 9(11):1329-1338. PubMed ID: 27638666 [TBL] [Abstract][Full Text] [Related]
56. In vivo protection against interleukin-1-induced articular cartilage damage by transforming growth factor-beta 1: age-related differences. van Beuningen HM; van der Kraan PM; Arntz OJ; van den Berg WB Ann Rheum Dis; 1994 Sep; 53(9):593-600. PubMed ID: 7979598 [TBL] [Abstract][Full Text] [Related]
57. A novel paradigm for dendritic cells as effectors of cartilage destruction. Lakey RL; Morgan TG; Rowan AD; Isaacs JD; Cawston TE; Hilkens CM Rheumatology (Oxford); 2009 May; 48(5):502-7. PubMed ID: 19269957 [TBL] [Abstract][Full Text] [Related]
58. Role of interleukin 1 in antigen-induced exacerbations of murine arthritis. van de Loo AA; Arntz OJ; Bakker AC; van Lent PL; Jacobs MJ; van den Berg WB Am J Pathol; 1995 Jan; 146(1):239-49. PubMed ID: 7856731 [TBL] [Abstract][Full Text] [Related]
59. Membrane-associated IL-1 contributes to chronic synovitis and cartilage destruction in human IL-1 alpha transgenic mice. Niki Y; Yamada H; Kikuchi T; Toyama Y; Matsumoto H; Fujikawa K; Tada N J Immunol; 2004 Jan; 172(1):577-84. PubMed ID: 14688369 [TBL] [Abstract][Full Text] [Related]
60. Protection against cartilage proteoglycan synthesis inhibition by antiinterleukin 1 antibodies in experimental arthritis. van de Loo FA; Arntz OJ; Otterness IG; van den Berg WB J Rheumatol; 1992 Mar; 19(3):348-56. PubMed ID: 1578447 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]